Quantitative Multiplex Immunofluorescence Evaluation of the Tumor Microenvironment in Pretreatment Tumors of Patients with Metastatic Breast Cancer and Serous Ovarian Carcinoma Treated with Liposomal Eribulin.
Douglas K MarksJohn KucharczykPan KimDonian I ChyongRobyn D GartrellYan LuHanina HibshooshHua GuoThomas R Jeffry EvansJuanita LopezRebecca KristeleitEileen ConnollyYvonne SaengerKevin KalinskyPublished in: Cancer investigation (2021)
Eribulin inhibits microtubule polymerization and suppresses epithelial-mesenchymal transition. Conventional pathology approaches have not identified a precise predictive biomarker for Eribulin. We performed qmIF on pre-treatment tissue from 11 patients (6 TNBC, 5 HGSOC) treated with Eribulin-LF. T-lymphocytes were the dominant immune-subset in TME, with higher levels detected in stroma vs tumor (9% vs 2%). Greater density of CD3+ (p = 0.01) and CD3 + CD8+ (p = 0.03) cells and closer proximity between CD3 + CD8+ and tumor cells was observed in the patients with disease control (PR + SD) vs. progressive disease. QmIF identified an association between TIL infiltration and Eribulin-LF sensitivity, which should be evaluated further in prospective studies.
Keyphrases
- metastatic breast cancer
- epithelial mesenchymal transition
- newly diagnosed
- end stage renal disease
- signaling pathway
- chronic kidney disease
- induced apoptosis
- ejection fraction
- multiple sclerosis
- transforming growth factor
- prognostic factors
- high throughput
- high resolution
- clinical trial
- mass spectrometry
- replacement therapy
- case control